Tweets
When you sign up to bike the ACR Virtual 5k, but it’s 62 degrees and beautiful in MN in November, you keep going and make it 20k.#acr21 #RheumPix https://t.co/j1Smoga41r
Julie Jones 🏳️🌈🐈⬛🐈 @JonesN4Rheum ( View Tweet )
4 years 8 months ago
and for those interested in the detail:
- remnant TAB divided and culture ex vivo with placebo, mavrilimumab, tocilizumab
- inflamm transcriptomics panel
- 81 differentially expressed genes assessed
- categorised by function https://t.co/0MWZk82Gj5
David Liew @drdavidliew ( View Tweet )
4 years 8 months ago
Great start to #ACR21 and great recap of the year in rheumatology.
Positive data on tofacitinib and AS but still pending approval.
Where would JAKinibs be in your AS treatment algorithm?🤔
@RheumNow https://t.co/cs8U33355A
Robert B Chao, MD @doctorRBC ( View Tweet )
4 years 8 months ago
#ACR21 Abst#0910 by @rheum_cat. Do TNFi ⬆️ risk of incident HTN in AxSpa?
⭐️PSOAS cohort: Prosp study from 2003-2018
▶️When adjusted for confounders (obesity, disease activity, NSAID use), insufficient evidence to show ⬆️ risk of HTN w TNFi
https://t.co/DCZ3W8CkOa @Rheumnow
Links:
Eric Dein @ericdeinmd ( View Tweet )
4 years 8 months ago
Exciting day at #ACR21
I wrote an article discussing COVID 19 in #RheumatoidArthritis discussing the following abstracts
0097 by Hasseli
1445 by @NamrataRheum
L04 by @rheum_cat & @rheum_covid
@rheumnow #COVID19 #RA #JAK #Rituximab
https://t.co/g32ZYHBjQY
Akhil Sood MD @AkhilSoodMD ( View Tweet )
4 years 8 months ago
#ACR21 Abst#0916. https://t.co/uc5JDVY0ud
Your patient has had 1 yr of remission of AxSpa on Certolizumab pegol, tolerating the medication. What do you recommend @Rheumnow
Links:
Eric Dein @ericdeinmd ( View Tweet )
4 years 8 months ago
Dr. Thaissa Cotton on SLE + ILD and/or myositis: important given poorer outcomes. Ask pts and listen to those lungs!
💠1.8 cases/100 patient years (14/551 pts in study)
💠92.9% had >=1 med-to-high titer marker
💠⬆️risk if baseline +anti KL-6, Ku, CENPB
#ACR21 Abst#0330 @RheumNow
Pedro Castillo @_Castillo_Pedro ( View Tweet )
4 years 8 months ago
#ACR21 Abst#0916
⭐️AxSpa pts in remission: Full Certolizumab vs 1/2 dose vs PBO
▶️ 85% w/o flare in full dose, 80% in 1/2 dose, just 23% in PBO
▶️ PBO pts with NO flare STILL showed ⬆️ ASDAS, BASDAI, and CRP
🔥Would ⬇️ not d/c Cimzia!
@Rheumnow https://t.co/uc5JDVY0ud #ACRBest https://t.co/fOssPlTEwR
Links:
Eric Dein @ericdeinmd ( View Tweet )
4 years 8 months ago
We are live! Join us!
RheumNow Daily Recap - #ACR21 https://t.co/hUqx6B2ySD via @YouTube
Links:
Dr. John Cush @RheumNow ( View Tweet )
4 years 8 months ago
Small numbers but mirrors data from TENOR and plenty to think about here. We clearly want to see sustained remission and Ax details, but very promising!
Definitely on the agenda for the @RheumNow #ACR21 GCA/PMR panel on Wed am with @LCalabreseDO @Sarah_L_Mackie @RichardPAConway
David Liew @drdavidliew ( View Tweet )
4 years 8 months ago
@benjaminsutu @RheumNow Always steroids first, we learned that the hard way in GUSTO - but yeah, probably something after that, and TCZ is our only b/tsDMARD choice... for the time being
(at #ACR21 - mavrilimumab, baricitinib, secukinumab...)
David Liew @drdavidliew ( View Tweet )
4 years 8 months ago
Dr. Petri noted that 1 week off of immunosuppressants is adequate for most lupus patients to mount a response. She avoided RTX during the pandemic. In pts who have had inadequate response to 2 or 3 doses of mRNA, she switches them to J&J. #ACR21 #COVI19 CH @rheumnow https://t.co/qNjmx9uTLF
TheDaoIndex @KDAO2011 ( View Tweet )
4 years 8 months ago
